Biohaven Ltd. (BHVN) Stock Forecast & Price Target

Compare

845 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BHVN Analyst Ratings

Strong Buy

9 Buy

3 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Biohaven

Ltd.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BHVN Stock 12 Month Forecast

Average Price Target

$20.44

▲(128.94% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Biohaven Ltd. in the last 3 months. The average price target is $20.44 with a high forecast of $30.00 and a low forecast of $10.00. The average price target represents a 128.94% change from the last price of $8.93.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","23":"$23","38":"$38","15.5":"$15.5","30.5":"$30.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.444444444444446,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,15.5,23,30.5,38],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.81,13.20923076923077,14.608461538461539,16.00769230769231,17.40692307692308,18.806153846153848,20.205384615384617,21.604615384615386,23.003846153846155,24.403076923076924,25.802307692307693,27.201538461538462,28.60076923076923,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.81,12.474188034188035,13.138376068376068,13.802564102564103,14.466752136752138,15.130940170940171,15.795128205128206,16.45931623931624,17.123504273504274,17.78769230769231,18.451880341880344,19.116068376068377,19.780256410256413,{"y":20.444444444444446,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.81,11.670769230769231,11.531538461538462,11.392307692307693,11.253076923076923,11.113846153846154,10.974615384615385,10.835384615384616,10.696153846153846,10.556923076923077,10.417692307692308,10.278461538461539,10.13923076923077,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":37.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.96,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.71,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.89,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.82,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.32,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.29,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.75,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.81,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$30.00

Average Price Target$20.44

Lowest Price Target$10.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Tyler Van Buren

TD Cowen

$15→$30

Buy

235.95%

Upside

Assigned

03/11/26

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (NASDAQ: PRAX), Biohaven Ltd. (NYSE: BHVN) and Siemens Healthineers AG (Other OTC: SEMHF)

Leonid Timashev

RBC Capital

$23

Buy

157.56%

Upside

Reiterated

03/11/26

Analysts Are Bullish on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Allogene Therapeutics (ALLO)

Corinne Johnson

Goldman Sachs

$24→$27

Buy

202.35%

Upside

Reiterated

03/10/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Dyne Therapeutics (NASDAQ: DYN), Biohaven Ltd. (NYSE: BHVN) and Teladoc (NYSE: TDOC)

Terence Flynn

Morgan Stanley

$21

Buy

135.16%

Upside

Reiterated

03/09/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Christopher Raymond

Raymond James

―

Buy

―

Reiterated

03/09/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Dina Ramadane

Bank of America Securities

$14

Hold

56.77%

Upside

Reiterated

03/09/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Atai Beckley N.V. (NASDAQ: ATAI), BridgeBio Oncology Therapeutics (NASDAQ: BBOT) and Biohaven Ltd. (NYSE: BHVN)

Douglas Tsao

H.C. Wainwright

$10

Hold

11.98%

Upside

Assigned

03/08/26

Analysts Conflicted on These Healthcare Names: Biohaven Ltd. (NYSE: BHVN) and Atai Beckley N.V. (NASDAQ: ATAI)

Myles Minter

William Blair

―

Hold

―

Reiterated

03/03/26

Maintaining Hold on Biohaven: Encouraging Early Signals but Awaiting Placebo-Controlled Data and Funding Clarity

Allison Bratzel

Piper Sandler

$30

Buy

235.95%

Upside

Reiterated

03/03/26

Biohaven Ltd. (BHVN) Gets a Buy from Piper Sandler

Samantha Semenkow

Citi

$14

Buy

56.77%

Upside

Reiterated

02/18/26

Analysts Conflicted on These Healthcare Names: Biohaven Ltd. (NYSE: BHVN), Olema Pharmaceuticals (NASDAQ: OLMA) and Hims & Hers Health (NYSE: HIMS)

Tessa Romero

J.P. Morgan

―

Buy

―

Reiterated

12/26/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Novavax (NASDAQ: NVAX), Xenon (NASDAQ: XENE) and Biohaven Ltd. (NYSE: BHVN)

Marc Goodman

Leerink Partners

$50→$15

Buy

67.97%

Upside

Reiterated

12/25/25

Biohaven: MDD Setback but Epilepsy Refocus and Diversified Pipeline Support Continued Buy Rating

Ashwani Verma

UBS

$26→$11

Hold

23.18%

Upside

Downgraded

11/28/25

Cautious Hold Rating on Biohaven Ltd. Amidst R&D Setbacks and Competitive Challenges

Thomas Shrader

BTIG

$16

Buy

79.17%

Upside

Reiterated

11/17/25

Strategic Positioning and Growth Potential Drive Buy Rating for Biohaven Ltd.

William Pickering

Bernstein

$34→$9

Hold

0.78%

Upside

Downgraded

11/06/25

Hold Rating on Biohaven Ltd. Amid Liquidity Challenges and Uncertain Clinical Outcomes

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Tyler Van Buren

TD Cowen

$15→$30

Buy

235.95%

Upside

Assigned

03/11/26

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (NASDAQ: PRAX), Biohaven Ltd. (NYSE: BHVN) and Siemens Healthineers AG (Other OTC: SEMHF)

Leonid Timashev

RBC Capital

$23

Buy

157.56%

Upside

Reiterated

03/11/26

Analysts Are Bullish on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Allogene Therapeutics (ALLO)

Corinne Johnson

Goldman Sachs

$24→$27

Buy

202.35%

Upside

Reiterated

03/10/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Dyne Therapeutics (NASDAQ: DYN), Biohaven Ltd. (NYSE: BHVN) and Teladoc (NYSE: TDOC)

Terence Flynn

Morgan Stanley

$21

Buy

135.16%

Upside

Reiterated

03/09/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Christopher Raymond

Raymond James

―

Buy

―

Reiterated

03/09/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Dina Ramadane

Bank of America Securities

$14

Hold

56.77%

Upside

Reiterated

03/09/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Atai Beckley N.V. (NASDAQ: ATAI), BridgeBio Oncology Therapeutics (NASDAQ: BBOT) and Biohaven Ltd. (NYSE: BHVN)

Douglas Tsao

H.C. Wainwright

$10

Hold

11.98%

Upside

Assigned

03/08/26

Analysts Conflicted on These Healthcare Names: Biohaven Ltd. (NYSE: BHVN) and Atai Beckley N.V. (NASDAQ: ATAI)

Myles Minter

William Blair

―

Hold

―

Reiterated

03/03/26

Maintaining Hold on Biohaven: Encouraging Early Signals but Awaiting Placebo-Controlled Data and Funding Clarity

Allison Bratzel

Piper Sandler

$30

Buy

235.95%

Upside

Reiterated

03/03/26

Biohaven Ltd. (BHVN) Gets a Buy from Piper Sandler

Samantha Semenkow

Citi

$14

Buy

56.77%

Upside

Reiterated

02/18/26

Analysts Conflicted on These Healthcare Names: Biohaven Ltd. (NYSE: BHVN), Olema Pharmaceuticals (NASDAQ: OLMA) and Hims & Hers Health (NYSE: HIMS)

Tessa Romero

J.P. Morgan

―

Buy

―

Reiterated

12/26/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Novavax (NASDAQ: NVAX), Xenon (NASDAQ: XENE) and Biohaven Ltd. (NYSE: BHVN)

Marc Goodman

Leerink Partners

$50→$15

Buy

67.97%

Upside

Reiterated

12/25/25

Biohaven: MDD Setback but Epilepsy Refocus and Diversified Pipeline Support Continued Buy Rating

Ashwani Verma

UBS

$26→$11

Hold

23.18%

Upside

Downgraded

11/28/25

Cautious Hold Rating on Biohaven Ltd. Amidst R&D Setbacks and Competitive Challenges

Thomas Shrader

BTIG

$16

Buy

79.17%

Upside

Reiterated

11/17/25

Strategic Positioning and Growth Potential Drive Buy Rating for Biohaven Ltd.

William Pickering

Bernstein

$34→$9

Hold

0.78%

Upside

Downgraded

11/06/25

Hold Rating on Biohaven Ltd. Amid Liquidity Challenges and Uncertain Clinical Outcomes

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Biohaven Ltd.

3 Months

xxx

Success Rate

10/22 ratings generated profit

Average Return

+6.10%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 45.45% of your transactions generating a profit, with an average return of +6.10% per trade.

1 Year

Thomas ShraderBTIG

Success Rate

10/22 ratings generated profit

Average Return

+19.58%

Copying Thomas Shrader's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +19.58% per trade.

2 Years

xxx

Success Rate

5/22 ratings generated profit

Average Return

-27.32%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 22.73% of your transactions generating a profit, with an average return of -27.32% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BHVN Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BHVN has received 12 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. BHVN average Analyst price target in the past 3 months is 20.44.

Each month's total comprises the sum of three months' worth of ratings.

BHVN Financial Forecast

BHVN Earnings Forecast

Next quarter’s earnings estimate for BHVN is -$0.84 with a range of -$1.15 to -$0.61. The previous quarter’s EPS was -$1.21. BHVN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year BHVN has Performed in-line its overall industry.

No data currently available

BHVN Sales Forecast

Next quarter’s sales forecast for BHVN is $327.00K with a range of $0.00 to $2.94M. The previous quarter’s sales results were $0.00. BHVN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year BHVN has Performed in-line its overall industry.

BHVN Stock Forecast FAQ

What is BHVN’s average 12-month price target, according to analysts?

Based on analyst ratings, Biohaven Ltd.’s 12-month average price target is 20.44.

What is BHVN’s upside potential, based on the analysts’ average price target?

Biohaven Ltd. has 128.94% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BHVN a Buy, Sell or Hold?

Biohaven Ltd. has a consensus rating of Strong Buy which is based on 9 buy ratings, 3 hold ratings and 0 sell ratings.

What is Biohaven Ltd.’s price target?

The average price target for Biohaven Ltd. is 20.44. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $30.00 ,the lowest forecast is $10.00. The average price target represents 128.94% Increase from the current price of $8.93.

What do analysts say about Biohaven Ltd.?

Biohaven Ltd.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of BHVN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Biohaven Ltd. (BHVN) Stock Forecast & Price Target

BHVN Analyst Ratings

BHVN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Biohaven Ltd.

BHVN Analyst Recommendation Trends

BHVN Financial Forecast

BHVN Earnings Forecast

BHVN Sales Forecast

BHVN Stock Forecast FAQ

Detailed List of Analyst Forecasts